Entities / Company
Collegium Pharmaceutical (United States).
company in Dedham, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 52
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Gone quiet
No new reports in 90+ days-
Collegium Pharmaceutical (US) stock performance lagged S&P 500 composite on August 7, 2025.Some support3 reports
-
Collegium Pharmaceutical reported on August 14, 2025, that the company enjoys steady growth across its pain portfolio, driven by its successful ADHD therapy product, Jornay.Some support7 reports
-
Collegium Pharmaceutical announced upgraded revenue guidance and a buyback program on August 21, leading to market reassessment.Some support1 report1 development inside
-
Jefferies facilitated a share repurchase agreement for Collegium Pharmaceutical.Speculative1 report
-
Analysts have set price targets and positive earnings estimate revisions for Collegium Pharmaceutical (Q104480182) based on company expectations.Some support3 reports
-
Zacks used its ranking system to find great stocks, involving Collegium Pharmaceutical.Some support1 report
-
Collegium Pharmaceutical and Bristol-Myers Squibb are both companies operating within the branded pharmaceuticals segment.Some support4 reports
-
Collegium Pharmaceutical appointed Vikram Karnani as President and CEO and Colleen Tupper as CFO on August 7, 2025.Some support1 report
-
Collegium Pharmaceutical (US) noted an industry growth forecast of 8.0% in the US on August 9, 2025.Some support2 reports
-
Collegium Pharmaceutical acquired Ironshore Therapeutics in 2024 and is scheduled to present pain studies at PAINWeek 2025.Well supported4 reports1 development inside
-
Collegium Pharmaceutical reported that its free cash flow declined over the last year, while a negative accrual ratio indicated FCF exceeded statutory profit.Some support1 report
-
Collegium Pharmaceutical's headquarters are located in Stoughton, Massachusetts, and Cheryl Wheeler serves as Head of Corporate Communications.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Collegium Pharmaceutical (United States) this week
News at the entities that move Collegium Pharmaceutical (United States) most-
Market Shared contextTrump's pledge to unleash oil and gas is reported to benefit US stocks, involving Diamond Hill Investment Group.Moves Collegium Pharmaceutical (United States)
Connections
The 2 strongest of 52, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Jefferies & Company Transactional
Jefferies facilitated financial agreements, including a share repurchase, for Collegium Pharmaceutical.
-
Market Shared context
Collegium Pharmaceutical's financial performance and operational updates are contextualized against the general market.
History
Events by the month they beganJune 2026
12 events- Collegium Pharmaceutical (US) stock performance lagged S&P 500 composite on August 7, 2025.
- Collegium Pharmaceutical reported on August 14, 2025, that the company enjoys steady growth across its pain portfolio, driven by its successful ADHD therapy product, Jornay.
- Collegium Pharmaceutical announced upgraded revenue guidance and a buyback program on August 21, leading to market reassessment.
- Jefferies facilitated a share repurchase agreement for Collegium Pharmaceutical.
- Analysts have set price targets and positive earnings estimate revisions for Collegium Pharmaceutical (Q104480182) based on company expectations.
- Zacks used its ranking system to find great stocks, involving Collegium Pharmaceutical.
- Collegium Pharmaceutical and Bristol-Myers Squibb are both companies operating within the branded pharmaceuticals segment.
- Collegium Pharmaceutical appointed Vikram Karnani as President and CEO and Colleen Tupper as CFO on August 7, 2025.
- Collegium Pharmaceutical (US) noted an industry growth forecast of 8.0% in the US on August 9, 2025.
- Collegium Pharmaceutical acquired Ironshore Therapeutics in 2024 and is scheduled to present pain studies at PAINWeek 2025.
- Collegium Pharmaceutical reported that its free cash flow declined over the last year, while a negative accrual ratio indicated FCF exceeded statutory profit.
- Collegium Pharmaceutical's headquarters are located in Stoughton, Massachusetts, and Cheryl Wheeler serves as Head of Corporate Communications.